Mergers & Acquisitions

• Future Electronics Inc. in its $3.8 billion sale to WT Microelectronics (TAIEX: 3036).
• NET Power, LLC (NYSE: NPWR) in its $1.459 billion business combination with Rice Acquisition Corp. II.
• Monterey Capital Acquisition Corporation (NASDAQ: MCAC) in its proposed $145 million business combination with ConnectM Technology Solutions, Inc.
• GRI Bio, Inc. (NASDAQ: GRI) in its reverse merger with Vallon Pharmaceuticals, Inc.
• Biolog-id S.A. in its proposed $312 million business combination with Genesis Growth Tech Acquisition Corp. (NASDAQ: GGAA).
• Hyperfine, Inc. (NASDAQ: HYPR) and Liminal Sciences in their $580 million business combination with HealthCor Catalio Acquisition Corp.
• The Metals Company (NASDAQ: TMC), formerly DeepGreen Metals Inc., in its $2.9 billion business combination with Sustainable Opportunities Acquisition Corporation.
• Quantum-Si Incorporated (NASDAQ: QSI) in its $1.46 billion business combination with HighCape Capital Acquisition Corp.
• Butterfly Network, Inc. (NYSE: BFLY) in its $1.5 billion business combination with Longview Acquisition Corp.
• DermTech, Inc. (NASDAQ: DMTK) in its business combination with Constellation Alpha Capital Corp.
• Solarflare Communications, Inc. in its approximately $400 million merger with Xilinx, Inc. (NASDAQ: XLNX).
• Karmadata, Inc. in its sale to Tabula Rasa HealthCare Inc. (NASDAQ: TRHC).
• Quantum-Si Incorporated (NASDAQ: QSI) in its acquisition of Majelac Technologies LLC.
• Enterprise Networking Solutions Inc. in its sale to Fulcrum Technology Group.

Capital Markets Transactions

• CervoMed Inc. in its $149.4 million PIPE financing.
• The selling securityholders in a $198.5 million underwritten secondary offering of Symbotic Inc. (NASDAQ: SYM) common stock.
• GRI Bio, Inc. in its $5.5 million public offering.
• DermTech, Inc. in its $65 million PIPE financing, $143.7 million underwritten public offering and at-the-market offerings.
• Inhibrx, Inc. in its $137 million initial public offering.
• Fulgent Genetics, Inc. in underwritten and at-the-market offerings.
• Exagen Inc. in its $50 million at-the-market offering.

Venture Capital & Emerging Companies

• Classy, Inc. in venture financings.
• Xendee Corporation in its $12 million Series A financing.
• FAScinate Therapeutics in its Series A financing.
• Curvo Labs, Inc. in its $2 million Series A financing.
• Decon7 Systems, Inc. in its financing transaction with Johnsonville Holdings, Inc.
• Oberon Fuels, Inc. in multiple financings.
• Interleukin Combinatorial Therapies in its Series A-1 financing.